Lipopolysaccharide of Aggregatibacter actinomycetemcomitans up-regulates inflammatory cytokines, prostaglandin E2 synthesis and osteoclast formation in interleukin-1 receptor antagonist-deficient mice

Journal of Periodontal Research

Volumn 48, Issue 6, 2013, Pages 748-756

  Mizutani, H ^a   Ishihara, Y ^a   Izawa, A ^a   Fujihara, Y ^a   Kobayashi, S ^a   Gotou, H ^a   Okabe, E ^a   Takeda, H ^a   Ozawa, Y ^a   Kamiya, Y ^a   Kamei, H ^a   Kikuchi, T ^a   Yamamoto, G ^a   Mitani, A ^a   Nishihara, T ^b   Noguchi, T ^a  

^a AICHI GAKUIN UNIVERSITY   (Japan)

^b KYUSHU DENTAL COLLEGE   (Japan)

Author keywords

Cyclooxygenase 2; Periodontal disease; Prostaglandin E2; Prostanoid receptor EP4

Indexed keywords

ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CYCLOOXYGENASE 2; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 6; ISOENZYME; LIPOPOLYSACCHARIDE; PROSTAGLANDIN E RECEPTOR 4; PROSTAGLANDIN E2; PTGS2 PROTEIN, MOUSE; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TARTRATE-RESISTANT ACID PHOSPHATASE; TNFRSF11A PROTEIN, MOUSE; TUMOR NECROSIS FACTOR ALPHA;

AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ANIMAL; ARTICLE; BAGG ALBINO MOUSE; BONE MARROW CELL; COMPARATIVE STUDY; CULTURE TECHNIQUE; CYCLOOXYGENASE-2; DRUG EFFECT; GENETICS; GIANT CELL; IMMUNOLOGY; INBRED MOUSE STRAIN; KNOCKOUT MOUSE; METABOLISM; MOUSE; OSTEOCLAST; OSTEOLYSIS; PERIODONTAL DISEASE; PERITONEUM MACROPHAGE; PHYSIOLOGY; SKULL; UPREGULATION;

CYCLOOXYGENASE-2; PERIODONTAL DISEASE; PROSTAGLANDIN E2; PROSTANOID RECEPTOR EP4;

ACID PHOSPHATASE; AGGREGATIBACTER ACTINOMYCETEMCOMITANS; ANIMALS; BONE MARROW CELLS; BONE RESORPTION; CELL CULTURE TECHNIQUES; CYCLOOXYGENASE 2; CYTOKINES; DINOPROSTONE; GIANT CELLS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1ALPHA; INTERLEUKIN-1BETA; INTERLEUKIN-6; ISOENZYMES; LIPOPOLYSACCHARIDES; MACROPHAGES, PERITONEAL; MICE; MICE, INBRED BALB C; MICE, INBRED STRAINS; MICE, KNOCKOUT; OSTEOCLASTS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; RECEPTORS, PROSTAGLANDIN E, EP4 SUBTYPE; SKULL; TUMOR NECROSIS FACTOR-ALPHA; UP-REGULATION;

EID: 84885600361     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/jre.12065     Document Type: Article

References (41)

1. Zijnge V, Ammann T, Thurnheer T, Gmur R. Subgingival biofilm structure. Front Oral Biol 2012;15:1-16.
2. Teles RP, Gursky LC, Faveri M et al. Relationships between subgingival microbiota and GCF biomarkers in generalized aggressive periodontitis. J Clin Periodontol 2010;37:313-323.
3. Heitz-Mayfield LJ. Disease progression: identification of high-risk groups and individuals for periodontitis. J Clin Periodontol 2005;32:196-209.
4. Kinane DF, Peterson M, Stathopoulou PG. Environmental and other modifying factors of the periodontal diseases. Periodontol 2000 2006;40:107-119.
5. Beck JD. Methods of assessing risk for periodontitis and developing multifactorial models. J Periodontol 1994;65:468-478.
6. Zambon JJ. Periodontal diseases: microbial factors. Ann Periodontol 1996;1:879-925.
7. Wilson M, Henderson B. Virulence factors of Actinobacillus actinomycetemcomitans relevant to the pathogenesis of inflammatory periodontal diseases. FEMS Microbiol Rev 1995;17:365-379.
8. Iino Y, Hopps RM. The bone-resorbing activities in tissue culture of lipopolysaccharides from the bacteria Actinobacillus actinomycetemcomitans, Bacteroides gingivalis and Capnocytophaga ochracea isolated from human mouths. Arch Oral Biol 1984;29:59-63.
9. Ishihara Y, Nishihara T, Maki E, Noguchi T, Koga T. Role of interleukin-1 and prostaglandin in in vitro bone resorption induced by Actinobacillus actinomycetemcomitans lipopolysaccharide. J Periodontal Res 1991;26:155-160.
10. Ito HO, Shuto T, Takada H et al. Lipopolysaccharides from Porphyromonas gingivalis, Prevotella intermedia and Actinobacillus actinomycetemcomitans promote osteoclastic differentiation in vitro. Arch Oral Biol 1996;41:439-444.
11. Suda T, Takahashi N, Udagawa N, Jimi E, Gillespie MT, Martin TJ. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 1999;20:345-357.
12. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-550.
13. Dinarello CA. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 2011;117:3720-3732.
14. Ishihara Y, Nishihara T, Kuroyanagi T et al. Gingival crevicular interleukin-1 and interleukin-1 receptor antagonist levels in periodontally healthy and diseased sites. J Periodontal Res 1997;32:524-529.
15. Mercado FB, Marshall RI, Klestov AC, Bartold PM. Relationship between rheumatoid arthritis and periodontitis. J Periodontol 2001;72:779-787.
16. Firestein GS, Boyle DL, Yu C et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994;37:644-652.
17. Horai R, Asano M, Sudo K et al. Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. J Exp Med 1998;187:1463-1475.
18. Horai R, Saijo S, Tanioka H et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-320.
19. Zhou Q, Desta T, Fenton M, Graves DT, Amar S. Cytokine profiling of macrophages exposed to Porphyromonas gingivalis, its lipopolysaccharide, or its FimA protein. Infect Immun 2005;73:935-943.
20. Koga T, Nishihara T, Fujiwara T et al. Biochemical and immunobiological properties of lipopolysaccharide (LPS) from Bacteroides gingivalis and comparison with LPS from Escherichia coli. Infect Immun 1985;47:638-647.
21. Nishihara T, Koga T, Hamada S. Suppression of murine macrophage interleukin-1 release by the polysaccharide portion of Haemophilus actinomycetemcomitans lipopolysaccharide. Infect Immun 1988;56:619-625.
22. Li X, Udagawa N, Takami M, Sato N, Kobayashi Y, Takahashi N. p38 Mitogen-activated protein kinase is crucially involved in osteoclast differentiation but not in cytokine production, phagocytosis, or dendritic cell differentiation of bone marrow macrophages. Endocrinology 2003;144:4999-5005.
23. Higuchi S, Tabata N, Tajima M et al. Induction of human osteoclast-like cells by treatment of blood monocytes with anti-fusion regulatory protein-1/CD98 monoclonal antibodies. J Bone Miner Res 1998;13:44-49.
24. Isoda K, Matsuki T, Kondo H, Iwakura Y, Ohsuzu F. Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB/c mice. Arterioscler Thromb Vasc Biol 2010;30:708-715.
25. Schett G, Redlich K, Hayer S et al. Osteoprotegerin protects against generalized bone loss in tumor necrosis factor-transgenic mice. Arthritis Rheum 2003;48:2042-2051.
26. Marsh CB, Moore SA, Pope HA, Wewers MD. IL-1ra suppresses endotoxin-induced IL-1 beta and TNF-alpha release from mononuclear phagocytes. Am J Physiol 1994;267:39-45.
27. Ishibe T, Kimura A, Ishida Y et al. Reduced acetaminophen-induced liver injury in mice by genetic disruption of IL-1 receptor antagonist. Lab Invest 2009;89:68-79.
28. Ono K, Kaneko H, Choudhary S et al. Biphasic effect of prostaglandin E2 on osteoclast formation in spleen cell cultures: role of the EP2 receptor. J Bone Miner Res 2005;20:23-29.
29. Noguchi K, Shitashige M, Yanai M et al. Prostaglandin production via induction of cyclooxygenase-2 by human gingival fibroblasts stimulated with lipopolysaccharides. Inflammation 1996;20:555-568.
30. Sato T, Morita I, Sakaguchi K et al. Involvement of prostaglandin endoperoxide H synthase-2 in osteoclast-like cell formation induced by interleukin-1 beta. J Bone Miner Res 1996;11:392-400.
31. Miyaura C, Inada M, Suzawa T et al. Impaired bone resorption to prostaglandin E2 in prostaglandin E receptor EP4-knockout mice. J Biol Chem 2000;275:19819-19823.
32. Yoshida K, Oida H, Kobayashi T et al. Stimulation of bone formation and prevention of bone loss by prostaglandin E EP4 receptor activation. Proc Natl Acad Sci U S A 2002;99:4580-4585.
33. Manolagas SC. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev 2000;21:115-137.
34. Rodan GA, Martin TJ. Therapeutic approaches to bone diseases. Science 2000;289:1508-1514.
35. Dobnig H, Turner RT. The effects of programmed administration of human parathyroid hormone fragment (1-34) on bone histomorphometry and serum chemistry in rats. Endocrinology 1997;138:4607-4612.
36. Pilbeam CC, Harrison JR, Raisz LG. Principles of Bone Biology. San Diego: Academic Press, 1996:715-728.
37. Lee YM, Fujikado N, Manaka H, Yasuda H, Iwakura Y. IL-1 plays an important role in the bone metabolism under physiological conditions. Int Immunol 2010;22:805-816.
38. Hashikawa T, Takedachi M, Terakura M et al. Activation of adenosine receptor on gingival fibroblasts. J Dent Res 2006;85:739-744.
39. Bresnihan B. Treatment of rheumatoid arthritis with interleukin 1 receptor antagonist. Ann Rheum Dis 1999;58:I96-I98.
40. Burls A, Jobanputra P. The trials of anakinra. Lancet 2004;364:827-828.
41. Baker PJ, Evans RT, Roopenian DC. Oral infection with Porphyromonas gingivalis and induced alveolar bone loss in immunocompetent and severe combined immunodeficient mice. Arch Oral Biol 1994;39:1035-1040.